Cargando…

Iron chelation may harm patients with COVID-19

Detalles Bibliográficos
Autores principales:	Garrick, Michael D., Ghio, Andrew J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459091/ https://www.ncbi.nlm.nih.gov/pubmed/32870379 http://dx.doi.org/10.1007/s00228-020-02987-w

Ejemplares similares

Correction to: Iron chelation may harm patients with COVID-19
por: Garrick, Michael D., et al.
Publicado: (2021)

Reply: Iron chelation may harm patients with COVID-19
por: Abobaker, Anis
Publicado: (2020)

Colchicine may not be effective in COVID-19 infection; it may even be harmful?
por: Cumhur Cure, Medine, et al.
Publicado: (2020)

Can iron chelation as an adjunct treatment of COVID-19 improve the clinical outcome?
por: Abobaker, Anis
Publicado: (2020)

Iron chelation in treatment of superficial siderosis
por: Derle, Eda
Publicado: (2018)

Comment on “Colchicine may not be effective in COVID-19 infection; it may even be harmful?”
por: Kobak, Senol
Publicado: (2020)

Should every Patient with MDS get Iron Chelation – Probably Yes
por: Ghosh, Kanjaksha, et al.
Publicado: (2017)

Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload
por: Alavi, Samin, et al.
Publicado: (2014)

Normal pregnancy in a patient with β-thalassaemia major receiving iron chelation therapy with deferasirox (Exjade®)
por: Vini, Dimitra, et al.
Publicado: (2011)

Impact of labile plasma iron and iron chelation on the viability of cultured mononuclear cells from patients undergoing autologous hematopoietic stem cell transplantation
por: Naoum, Flávio Augusto, et al.
Publicado: (2017)

Sophism in the Management of Acute Aluminum Phosphide Poisoning may Cause Patient Harm
por: Farahani, Maryam Vasheghani, et al.
Publicado: (2017)

Non-recommended medical interventions and their possible harm in patients with COVID-19
por: Pecho-Silva, Samuel, et al.
Publicado: (2021)

Serum iron may not be linked with migraine
por: Gupta, Ravi, et al.
Publicado: (2013)

Antenatal corticosteroids and COVID-19: balancing benefits and harms
por: Liauw, Jessica, et al.
Publicado: (2020)

Letter to the editors in response to: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic (Cure et al.)
por: Ekiz, Timur, et al.
Publicado: (2020)

Harm of early dexamethasone for COVID-19 and bias in randomized trials
por: Núñez, Isaac, et al.
Publicado: (2023)

Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19
por: Kavanagh, Oisín, et al.
Publicado: (2020)

First, do no harm: bilateral radial artery occlusion in a COVID-19 patient
por: Bouwhuis, Anne, et al.
Publicado: (2020)

Systemic corticosteroids for management of COVID-19: Saving lives or causing harm?
por: FakhriRavari, Alireza, et al.
Publicado: (2021)

A role for divalent metal transporter (DMT1) in mitochondrial uptake of iron and manganese
por: Wolff , Natascha A., et al.
Publicado: (2018)

Evaluation of clinical harm associated with Omicron hospital-onset COVID-19 infection
por: Otter, Jonathan A., et al.
Publicado: (2023)

DCCP and DICP: Construction and Analyses of Databases for Copper- and Iron-Chelating Proteins
por: Wu, Hao, et al.
Publicado: (2005)

COVID19, the pandemic which may exemplify a need for harm-reduction approaches to eating disorders: a reflection from a person living with an eating disorder
por: Janse van Rensburg, Margaret
Publicado: (2020)

Iron chelates hitch a ride on PAT1
por: Collins, James F.
Publicado: (2021)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
por: Taher, Ali T, et al.
Publicado: (2016)

May polyenthesitis follow COVID-19?
por: Ciaffi, Jacopo, et al.
Publicado: (2021)

Iron Chelator or Iron Supplement Consumption in COVID-19? The Role of Iron with Severity Infection
por: Bastin, Alireza, et al.
Publicado: (2021)

Liver injury in COVID-19 – The culprit may not be COVID-19!
por: Singh, Aditya, et al.
Publicado: (2021)

Prospective changes of pancreatic iron in patients with thalassemia major and association with chelation therapy
por: Meloni, Antonella, et al.
Publicado: (2022)

Ocular abnormalities in patients with beta thalassemia on transfusion and chelation therapy: Our experience
por: Jethani, Jitendra, et al.
Publicado: (2010)

Impact of COVID-19 on neonatal health: Are we causing more harm than good?
por: Smith, Hazel A.
Publicado: (2020)

The Harm in Kratom
por: Drago, Joshua Z., et al.
Publicado: (2017)

No Harm Done?
por: Crawford, Mike
Publicado: (1999)

Therapeutic potential of induced iron depletion using iron chelators in Covid-19
por: Poonkuzhi Naseef, Punnoth, et al.
Publicado: (2022)

The use of Traditional Chinese Medicines to treat SARS-CoV-2 may cause more harm than good
por: Gray, Paul E., et al.
Publicado: (2020)

Recovery from Covid-19 may be prolonged
por: Gupta, Harish, et al.
Publicado: (2021)

Adrenal Crisis May Occur Even In Patients With Asymptomatic Covid-19
por: Castinetti, Frederic, et al.
Publicado: (2020)

Neuropilin-1 may be responsible for retinal findings in patients with COVID-19
por: El‑Arabey, Amr Ahmed, et al.
Publicado: (2021)

Reply to “Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19”
por: Khan, Md. Saiful Islam, et al.
Publicado: (2021)

Migraine and restless leg syndrome co-morbidity may be due to iron deficiency
por: Yücel, Mehmet, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8oqb89buritdcqko7b25ki45aj